loading
Newamsterdam Pharma Company N V stock is traded at $8.90, with a volume of 6,655. It is down -1.33% in the last 24 hours and up +3.01% over the past month. NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
See More
Previous Close:
$9.02
Open:
$9.63
24h Volume:
6,655
Relative Volume:
0.94
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-33.08%
1M Performance:
+3.01%
6M Performance:
-3.26%
1Y Performance:
+0.00%
1-Day Range:
Value
$8.80
$9.75
1-Week Range:
Value
$8.80
$14.80
52-Week Range:
Value
$2.60
$16.75

Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile

Name
Name
Newamsterdam Pharma Company N V
Name
Phone
31 35 206 2971
Name
Address
Gooimeer 2-35, Naarden
Name
Employee
22
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
NAMSW's Discussions on Twitter

Compare NAMSW with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
NAMSW 8.90 0 0 0 0 0.00
VRTX 450.97 116.38B 10.63B -479.80M -1.35B 13.33
REGN 738.00 82.09B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.14B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.25B 3.30B -501.07M 1.03B 11.54

Newamsterdam Pharma Company N V Stock (NAMSW) Latest News

pulisher
Nov 21, 2024

Needham & Company LLC Reiterates Buy Rating for NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Nov 21, 2024
pulisher
Nov 21, 2024

NewAmsterdam Pharma Reports Promising Phase 3 Trial Results - Yahoo Finance

Nov 21, 2024
pulisher
Nov 20, 2024

NewAmsterdam Pharma target raised to $45 on strong trial data - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

Newamsterdam’s obicetrapib combo nails phase III LDL-C endpoints - BioWorld Online

Nov 20, 2024
pulisher
Nov 20, 2024

NewAmsterdam Pharma target raised to $45 on strong trial data By Investing.com - Investing.com UK

Nov 20, 2024
pulisher
Nov 20, 2024

NewAmsterdam Pharma stock falls on trial data (NAMS:NASDAQ) - Seeking Alpha

Nov 20, 2024
pulisher
Nov 20, 2024

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH - The Manila Times

Nov 20, 2024
pulisher
Nov 20, 2024

NewAmsterdam Pharma's Phase 3 Trial Shows 48.6% Cholesterol Reduction, Hits All Endpoints | NAMSW Stock News - StockTitan

Nov 20, 2024
pulisher
Nov 19, 2024

NewAmsterdam Pharma stock holds Overweight rating with catalysts ahead in Ph3 topline readouts - Investing.com

Nov 19, 2024
pulisher
Nov 19, 2024

Trend Tracker for (NAMSW) - Stock Traders Daily

Nov 19, 2024
pulisher
Nov 19, 2024

Frazier Life Sciences Bolsters Leadership with Two Senior Industry Veterans | NAMS Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 18, 2024

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 - The Manila Times

Nov 18, 2024
pulisher
Nov 15, 2024

RA Capital Management, L.P. Expands Stake in NewAmsterdam Pharma Co NV - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

GSA Capital Partners LLP Has $1.10 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) surges 13%; private equity firms who own 46% shares profited along with institutions - Simply Wall St

Nov 14, 2024
pulisher
Nov 13, 2024

When the Price of (NAMS) Talks, People Listen - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

Is NewAmsterdam Pharma (NAMS) Top Performing European Stock Heading into 2025? - Insider Monkey

Nov 13, 2024
pulisher
Nov 12, 2024

10 Top Performing European Stocks Heading into 2025 - Insider Monkey

Nov 12, 2024
pulisher
Nov 12, 2024

Lisanti Capital Growth LLC Invests $700,000 in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Nov 12, 2024
pulisher
Nov 11, 2024

NewAmsterdam Pharma Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga

Nov 11, 2024
pulisher
Nov 11, 2024

Q4 EPS Forecast for NewAmsterdam Pharma Reduced by Analyst - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

William Blair Issues Pessimistic Forecast for NAMS Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Leerink Partnrs Has Bullish Outlook for NAMS FY2024 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Equities Analysts Offer Predictions for NAMS FY2024 Earnings - Defense World

Nov 11, 2024
pulisher
Nov 10, 2024

Leerink Partnrs Has Strong Estimate for NAMS FY2028 Earnings - Defense World

Nov 10, 2024
pulisher
Nov 09, 2024

Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $33.80 - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

(NAMSW) Proactive Strategies - Stock Traders Daily

Nov 08, 2024
pulisher
Nov 08, 2024

What is Leerink Partnrs' Forecast for NAMS FY2028 Earnings? - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

NewAmsterdam Pharma Reports Strong Q3 and Trial Progress - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma - Benzinga

Nov 07, 2024
pulisher
Nov 07, 2024

Newamsterdam Pharma Faces Compliance Cost Surge as Emerging Growth Status Ends - TipRanks

Nov 07, 2024
pulisher
Nov 06, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Receives $33.80 Consensus PT from Analysts - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

NewAmsterdam Pharma Revenue Soars 900%, Reports Strong Q3 Results Ahead of Key Trial Data | NAMS Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 05, 2024

abrdn plc Purchases 53,060 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Nov 05, 2024
pulisher
Nov 03, 2024

(NAMS) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 01, 2024

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 01, 2024
pulisher
Oct 29, 2024

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November - The Manila Times

Oct 29, 2024
pulisher
Oct 25, 2024

Needham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN

Oct 25, 2024
pulisher
Oct 18, 2024

NewAmsterdam Pharma to Restate Prior Financials By Investing.com - Investing.com Australia

Oct 18, 2024
pulisher
Oct 18, 2024

NewAmsterdam Pharma to Restate Prior Financials - Investing.com India

Oct 18, 2024
pulisher
Oct 17, 2024

(NAMSW) Trading Report - Stock Traders Daily

Oct 17, 2024
pulisher
Oct 14, 2024

NewAmsterdam Pharma Breaks Above 200-Day Moving AverageBullish for NAMS - Nasdaq

Oct 14, 2024
pulisher
Oct 12, 2024

Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $33.80 - MarketBeat

Oct 12, 2024
pulisher
Oct 11, 2024

NewAmsterdam Pharma Company N.V. (NAMS) Price Target Increased by 8.93% to 31.11 - MSN

Oct 11, 2024
pulisher
Oct 11, 2024

Marshall Wace LLP Decreases Stake in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Oct 11, 2024
pulisher
Oct 07, 2024

When the Price of (NAMSW) Talks, People Listen - Stock Traders Daily

Oct 07, 2024
pulisher
Oct 05, 2024

Millennium Management LLC Has $22.39 Million Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Oct 05, 2024
pulisher
Oct 04, 2024

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies - Seeking Alpha

Oct 04, 2024
pulisher
Oct 01, 2024

NewAmsterdam Pharma executive sells shares worth $707,400 By Investing.com - Investing.com South Africa

Oct 01, 2024
pulisher
Oct 01, 2024

NewAmsterdam Pharma executive sells shares worth $707,400 - Investing.com India

Oct 01, 2024

Newamsterdam Pharma Company N V Stock (NAMSW) Financials Data

There is no financial data for Newamsterdam Pharma Company N V (NAMSW). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
Cap:     |  Volume (24h):